India covid-19 information patient India

Mylan gets approval for emergency use of remdesivir for Covid-19

Reading now: 564
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Mylan has secured regulatory approval from the Drug Controller General of India (DCGI) for restricted emergency use of 100mg/vial remdesivir lyophilized powder to treat Covid-19.

The approval is for suspected or laboratory-confirmed cases of Covid-19 in adults and children hospitalised with the severe form of the disease.

To be introduced under the brand name DESREM in India, the antiviral drug will be available to patients this month at a price of Rs4,800.

Mylan noted that the price is more than 80% lower compared to the price set for the branded version of remdesivir to governments of developed countries.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA